北京市中伦律师事务所 法律意见书 二〇二五年四月 法律意见书 关于福建傲农生物科技集团股份有限公司 2025 年第二次临时股东大会的 北京市中伦律师事务所 关于福建傲农生物科技集团股份有限公司 2025 年第二次临时股东大会的 致：福建傲农生物科技集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为福建傲农生物科技集团股 份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席 公司 2025 年第二次临时股东大会（以下简称"本次股东大会"）。本所律师根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）等有关法律、法规、规范性文件及《福建傲农生物科技集团股份 有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会进行见 证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律意见书 所必需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、 准确、完整的 ...

证券代码：603363 证券简称：*ST 傲农 公告编号：2025-047 福建傲农生物科技集团股份有限公司 2025 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 579 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 834,887,243 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 38.4462 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次临时股东大会由公司董事会召集，董事长苏明城主持，会议采取现场投票和 网络投票相结合方式召开并表决。会议的召集、召开、表决方式符合《公司法》 1、公司在任董事 9 人，出席 9 人； 2、公司在任监事 3 人，出席 3 人； 3、公司董事会秘书彭江先生出席本次会议，全体高级管理人员列席本次会议。 二、 议案审议情况 ...

Group 1 - *ST Jiayao (300108.SZ) has closed below 1 yuan for 12 consecutive trading days, and if it remains below 1 yuan for 20 consecutive trading days, it will face delisting [1] - *ST Longjin (002750.SZ) closed at 1.24 yuan per share on April 11, 2025, with a total market value of 497 million yuan; if the total market value remains below 500 million yuan for 20 consecutive trading days, it will face delisting [1] - *ST Aonong (603363.SH) has a negative net asset for 2023 and continuous losses, resulting in a delisting risk warning; if it does not meet the conditions to lift the warning in 2024, it will face delisting [1] Group 2 - *ST Pengbo (600804.SH) received an audit report with a disclaimer of opinion for 2023, leading to a delisting risk warning; if the 2024 financial report also receives a qualified or adverse opinion, it will face delisting [1] - *ST Dongyuan (002310.SZ) has a negative net asset for 2023 and continuous losses, resulting in a delisting risk warning; if the 2024 financial report triggers delisting conditions, it will face delisting [1] - *ST Gongzhi (000584.SZ) received an audit report with a disclaimer of opinion and a denied internal control report for 2023, leading to a delisting risk warning; if the 2024 financial or internal control report triggers delisting conditions, it will face delisting [2] Group 3 - *ST Xinning (300013.SZ) has a negative net asset for 2023, resulting in a delisting risk warning; if the 2024 financial report triggers delisting conditions, it will face delisting [2]

Core Viewpoint - The company, Fujian Aonong Biological Technology Group Co., Ltd., expects to achieve a net profit of between 200 million to 300 million yuan in the first quarter of 2025, marking a significant turnaround from losses in the previous year [2][4]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company between 200 million to 300 million yuan for Q1 2025, an increase of 492.02 million to 592.02 million yuan compared to the same period last year, indicating a turnaround from losses [2][4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -35 million to -45 million yuan, which represents a reduction in losses of 318.37 million to 328.37 million yuan compared to the previous year [2][4]. Group 2: Previous Year’s Performance - In the same period last year, the company reported a total loss of 377.90 million yuan, with a net loss attributable to shareholders of the parent company of 292.02 million yuan [6]. - The net profit after deducting non-recurring gains and losses was -363.37 million yuan, with a loss per share of -0.34 yuan [6][7]. Group 3: Reasons for Performance Improvement - The company has undergone bankruptcy restructuring, which has allowed it to divest idle assets, reduce operational burdens, and significantly lower debt and interest expenses [8]. - The price of live pigs has increased compared to the same period last year, while the company's breeding costs have decreased significantly, leading to profitability in the breeding segment [8]. - The company recognized some restructuring gains during the reporting period, although depreciation and amortization for units awaiting resumption of production have had a negative impact on profits [8][9].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300528 证券简称：幸福蓝海 公告编号：2025-010 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 天衡会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所未发生变更。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 □不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 2024年，幸福蓝海以习近平新时代中国特色社会主义思想为指导，在董事会的领导下，紧密围绕战略规 划，有序开展经营工作，科学部署，稳健经营，始终坚持把社会效益放在首位、实现社会效益和经济效 益相统一。在影视剧创作方 ...

证券代码：603363 证券简称：*ST 傲农 公告编号：2025-044 根据《上海证券交易所上市公司自律监管指南第 2 号——业务办理》第 十三号——退市风险公司信息披露规定，财务类退市风险公司应当在首次风险 提示公告披露后至年度报告披露前，每 10 个交易日披露一次风险提示公告。本 次公告为公司第六次风险提示公告，敬请广大投资者注意投资风险。 根据《上海证券交易所股票上市规则》的相关规定，若公司 2024 年年 度经审计的期末归属于上市公司股东的净资产为正值、年审会计师事务所对公 司 2024 年年度财务报告出具了标准的无保留意见审计报告，且不存在其他需要 实施退市风险警示的情形，公司将在董事会审议通过并披露 2024 年年度报告后 及时向上海证券交易所申请撤销对公司股票实施的退市风险警示。因经审计的 2024 年年度报告尚未披露，公司相关风险警示撤销仍存在不确定性，若公司不 符合《上海证券交易所股票上市规则》规定的撤销退市风险警示条件或者未在 规定期限内申请撤销退市风险警示，公司股票将被上海证券交易所终止上市， 敬请广大投资者注意投资风险。 一、可能被终止上市的原因 公司于 2024 年 4 月 30 ...

Financial Performance - Total revenue for the reporting period was CNY 876,267.28 million, a decrease of 54.97% compared to the same period last year[3] - The company achieved a net profit attributable to shareholders of CNY 57,934.50 million, reversing from a loss of CNY 365,082.22 million in the previous year[3] - The company reported a basic earnings per share of CNY 0.67, an increase of CNY 4.88 from the previous year[9] Assets and Equity - The total assets at the end of the reporting period were CNY 950,609.70 million, down 30.23% from the beginning of the period[9] - The equity attributable to shareholders increased to CNY 256,618.15 million, a significant increase of CNY 352,915.06 million compared to the previous year[9] Sales and Production - The company sold 1.7218 million tons of feed, a decrease of 36.70% year-on-year, with pig feed sales down 47.68%[5] - The company reported a significant reduction in live pig output, with 2.0984 million heads, down 64.19% year-on-year[5] Restructuring and Financial Impact - The company recognized a restructuring gain of approximately CNY 2,500 million during the reporting period[7] - Financial expenses amounted to approximately CNY 650 million, heavily impacting profitability due to ongoing restructuring[6] - The company has focused on stabilizing core assets and business operations while shutting down inefficient non-core assets[5]

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 200 million and 300 million CNY, an increase of 492.02 million to 592.02 million CNY compared to the same period last year, indicating a turnaround from loss to profit [2]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -35 million and -45 million CNY, a reduction in loss of 318.37 million to 328.37 million CNY compared to the same period last year [2]. - The total profit for the same period last year was -377.90 million CNY, with a net profit attributable to shareholders of the parent company at -292.02 million CNY [7]. Operational Improvements - The company achieved a significant reduction in operational burdens through bankruptcy restructuring, leading to a substantial decrease in debt scale and interest expenses [9]. - The rise in pig prices compared to the same period last year, along with a significant decrease in breeding costs, contributed to profitability in the breeding segment [9]. - The company recognized part of the restructuring gains during the reporting period, positively impacting financial performance [9]. Risk and Uncertainty - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast [10]. - The preliminary earnings forecast data is subject to final confirmation in the official Q1 2025 report, and investors are advised to be cautious regarding investment risks [11]. - The company’s stock has been warned of delisting risks due to negative net assets and consecutive annual losses from 2021 to 2023 [11].

Group 1 - The company held its 10th meeting of the 4th Board of Directors and the first extraordinary shareholders' meeting on January 7 and January 23, 2025, respectively, to approve the amendment of the company's articles of association and to handle business registration changes [1] - The company has completed the business registration change procedures and obtained a new business license from the Zhangzhou Market Supervision Administration [1] - The registered capital of the company is 2.6055826 billion yuan, and it was established on April 26, 2011 [1] Group 2 - The company's business scope includes research and development of biological feed, sales of livestock and fishery feed, sales of feed additives, and sales of agricultural products [1] - The company is also involved in various technical services, technology transfer, and investment activities [1] - The company operates under a unified social credit code of 91350600572989045Q and is classified as a publicly listed company [1]

证券代码：603363 证券简称：*ST 傲农 公告编号：2025-043 福建傲农生物科技集团股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 5、法定代表人：吴有林 1、名称：福建傲农生物科技集团股份有限公司 2、统一社会信用代码：91350600572989045Q 6、注册资本：贰拾陆亿零伍佰伍拾捌万贰仟陆佰贰拾陆圆整 7、成立日期：2011 年 04 月 26 日 8、经营范围：一般项目：生物饲料研发；畜牧渔业饲料销售；饲料添加剂 销售；饲料原料销售；粮食收购；农业科学研究和试验发展；技术服务、技术开 发、技术咨询、技术交流、技术转让、技术推广；食品销售（仅销售预包装食品）； 初级农产品收购；食用农产品初加工；食用农产品批发；农副产品销售；动物肠 衣加工；货物进出口；技术进出口；以自有资金从事投资活动（除依法须经批准 的项目外，凭营业执照依法自主开展经营活动）。许可项目：饲料生产；饲料添 加剂生产；兽药经营；食品生产；食品销售；食品互联网销售；互联网信息服务 （依法须经批准的项 ...